Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Colorectal cancer (2)
- Biomarker (1)
- Breast cancer (1)
- CAR-T cell therapy (1)
- Cancer biomarkers (1)
-
- Cancer prevention (1)
- Chimeric antigen receptor (CAR) (1)
- Esophageal cancer (1)
- GUCY2C (1)
- Gastric cancer (1)
- Gastrointestinal cancer (1)
- Guanylin (1)
- Guanylyl cyclase C (1)
- Hormone replacement (1)
- Immunotherapy (1)
- Linaclotide (1)
- Marked point patterns (1)
- Microscopic image analysis (1)
- Nearest neighbor distance (1)
- Plecanatide (1)
- Quantitative pathology (1)
- Spatial interactions (1)
- Spatially-resolved immunohistochemistry data (1)
- Tumor immune microenvironment (1)
- Tumor-associated macrophages (1)
- Uroguanylin (1)
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Guanylyl Cyclase C As A Diagnostic And Therapeutic Target In Colorectal Cancer, Adi Caspi, Ariana A. Entezari, Madison Crutcher, Adam E. Snook, Scott A. Waldman
Guanylyl Cyclase C As A Diagnostic And Therapeutic Target In Colorectal Cancer, Adi Caspi, Ariana A. Entezari, Madison Crutcher, Adam E. Snook, Scott A. Waldman
Department of Pharmacology and Experimental Therapeutics Faculty Papers
Colorectal cancer remains a major cause of mortality in the USA, despite advances in prevention and screening. Existing therapies focus primarily on generic treatment such as surgical intervention and chemotherapy, depending on disease severity. As personalized medicine and targeted molecular oncology continue to develop as promising treatment avenues, there has emerged a need for effective targets and biomarkers of colorectal cancer. The transmembrane receptor guanylyl cyclase C (GUCY2C) regulates intestinal homeostasis and has emerged as a tumor suppressor. Further, it is universally expressed in advanced metastatic colorectal tumors, as well as other cancer types that arise through intestinal metaplasia. In …
Targeting Gastrointestinal Cancers With Chimeric Antigen Receptor (Car)-T Cell Therapy, Ross E Staudt, Robert D Carlson, Adam E. Snook
Targeting Gastrointestinal Cancers With Chimeric Antigen Receptor (Car)-T Cell Therapy, Ross E Staudt, Robert D Carlson, Adam E. Snook
Department of Pharmacology and Experimental Therapeutics Faculty Papers
The immune system is capable of remarkably potent and specific efficacy against infectious diseases. For decades, investigators sought to leverage those characteristics to create immune-based therapies (immunotherapy) that might be far more effective and less toxic than conventional chemotherapy and radiation therapy for cancer. Those studies revealed many factors and mechanisms underlying the success or failure of cancer immunotherapy, leading to synthetic biology approaches, including CAR-T cell therapy. In this approach, patient T cells are genetically modified to express a chimeric antigen receptor (CAR) that converts T cells of any specificity into tumor-specific T cells that can be expanded to …
Spatial Metrics Of Interaction Between Cd163-Positive Macrophages And Cancer Cells And Progression-Free Survival In Chemo-Treated Breast Cancer, Brenton Maisel, Misung Yi, Amy R Peck, Yunguang Sun, Jeffrey A Hooke, Albert J Kovatich, Craig D Shriver, Hai Hu, Marja T Nevalainen, Takemi Tanaka, Nicole L Simone, Li Lily Wang, Hallgeir Rui, I Chervoneva
Spatial Metrics Of Interaction Between Cd163-Positive Macrophages And Cancer Cells And Progression-Free Survival In Chemo-Treated Breast Cancer, Brenton Maisel, Misung Yi, Amy R Peck, Yunguang Sun, Jeffrey A Hooke, Albert J Kovatich, Craig D Shriver, Hai Hu, Marja T Nevalainen, Takemi Tanaka, Nicole L Simone, Li Lily Wang, Hallgeir Rui, I Chervoneva
Department of Pharmacology and Experimental Therapeutics Faculty Papers
Tumor-associated macrophages (TAMs) promote progression of breast cancer and other solid malignancies via immunosuppressive, pro-angiogenic and pro-metastatic effects. Tumor-promoting TAMs tend to express M2-like macrophage markers, including CD163. Histopathological assessments suggest that the density of CD163-positive TAMs within the tumor microenvironment is associated with reduced efficacy of chemotherapy and unfavorable prognosis. However, previous analyses have required research-oriented pathologists to visually enumerate CD163+ TAMs, which is both laborious and subjective and hampers clinical implementation. Objective, operator-independent image analysis methods to quantify TAM-associated information are needed. In addition, since M2-like TAMs exert local effects on cancer cells through direct juxtacrine cell-to-cell interactions, …